FDA Neurology Digest: September 2026
The FDA approved several neurology drugs in September 2026. Ionis Pharmaceuticals' Zilganersen (Zanvastro) was approved for Alexander disease, Scholar Rock's apitegromab-mstn (Isembyld) for SMA, Ultragenyx's rebisufligene etisparvovec-hopf (Fayuvi) for Sanfilippo A, IntraBio's levacetylleucine (Aqneursa) for ataxia-telangiectasia, and AbbVie's Tavapadon (Juvmo) for Parkinson's. Azurity Pharmaceuticals' Lamlique, a liquid lamotrigine, was also approved for epilepsy.
How this was made
The 30-second read
Why it matters
These approvals represent significant pipeline milestones for the involved companies and could lift sector sentiment.
Market read
Multiple FDA approvals in neurology provide fresh catalysts for biotech stocks and may boost related ETFs.
What to watch
Potential manufacturing scale‑up challenges and payer coverage decisions.
Background
The FDA's September 2026 neurology digest lists five new approvals across rare neurological disorders.
Ticker impact
Ionis Pharmaceuticals received FDA approval for zilganersen for Alexander disease.
likely upward pressure as market prices in the new product launch
First FDA approval for a rare disease; investors typically reward biotech breakthroughs.
AbbVie received FDA approval for tavapadon for Parkinson's disease.
moderate upward pressure from added pipeline diversification
Large cap with existing momentum; new indication adds incremental upside.
Market effects
Biotech and rare‑disease sectors gain momentum from multiple FDA approvals.
U.S. biotech indices likely see modest gains.
International investors may reallocate to rare‑disease pipelines.
Counterpoint
Approval does not guarantee commercial uptake; reimbursement and competition could limit upside.
Key entities
- companyIonis Pharmaceuticals
Developer of zilganersen for Alexander disease.
- companyUltragenyx Pharmaceutical
Developer of rebisufligene etisparvovec-hopf for Sanfilippo A.
- companyAbbVie
Developer of tavapadon for Parkinson's disease.
